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Objectives: To explore the relation between non-invasive measures of cardiac function and sudden
cardiac death, as well as the development and utility of an index integrating these variables to identify
patients at increased risk of this mode of death.
Design: UK-HEART (United Kingdom-heart failure evaluation and assessment of risk trial) was a
prospective study conducted between December 1993 and April 2000. The study was specifically
designed to identify non-invasive markers of death and mode of death among patients with chronic heart
failure.
Setting: 8 UK general hospitals.
Main outcome measures: Death and mode of death.
Results: 553 patients aged a mean (SD) of 63 (10) years, in New York Heart Association functional class
2.3 (0.02), recruited prospectively. After 2365 patient-years’ follow up, 201 patients had died (67
suddenly). Predictors of sudden death were greater cardiothoracic ratio, QRS dispersion, QT dispersion
corrected for rate (QTc) across leads V1–V6 on the 12 lead ECG, and the presence of non-sustained
ventricular tachycardia. The hazard ratio and 95% confidence intervals (CI) of sudden death for a 10%
increase in cardiothoracic ratio was 1.43 (95% CI 1.20 to 1.71), for a 10% increase in QRS dispersion
1.11 (95% CI 1.04 to 1.19), for the presence of non-sustained ventricular tachycardia 2.03 (95% CI 1.27
to 3.25), and for a 10% increase in QTc dispersion across leads V1–V6 1.03 (95% CI 1.00 to 1.07) (all
p , 0.04). An index derived from these four factors performed well in identifying patients specifically at
increased risk of sudden death.
Conclusions: Results show that an index derived from three widely available non-invasive investigations
has the potential to identify ambulant patients with chronic heart failure at increased risk of sudden death.
This predictive tool could be used to target more sophisticated investigations or interventions aimed at
preventing sudden death.
C
hronic heart failure (CHF) is the most prevalent
cardiovascular disorder in western societies.1 Despite
the use of new drugs, patients with relatively mild
symptoms of CHF have a mortality approaching 10% a year.2
At least half of these deaths occur suddenly without warning.
In the Framingham study, the sudden death rate for patients
with CHF was almost 10 times the general age adjusted
population rate.3 The majority of patients with CHF have
relatively mild to moderate symptoms but are still at
significant risk of sudden death compared with patients
with more substantial functional impairment.2 4 5 Treatments
aimed at preventing sudden death and non-sudden death
require different strategies. Over the past 10 years implan-
table cardioverter-defibrillators have emerged as a potentially
effective treatment to prevent sudden death.6 7 However,
trials have focussed on patients with evidence of significantly
impaired left ventricular function and the population studied
has not been selected on the basis of symptoms and signs of
CHF.
Over 50% of patients with myocardial infarction who later
die suddenly have well preserved left ventricular function.8
Within the large population of patients with relatively
preserved left ventricular function and mild to moderate
CHF there is a subgroup at particularly high risk of sudden
death.9 Establishing reliable non-invasive predictors of
sudden death is hence important. There is no accurate
method of risk stratifying ambulant patients with the CHF
phenotype who are at increased risk of this mode of death.
The UK-HEART (United Kingdom-heart failure evaluation
and assessment of risk trial) prospectively explored the
prognostic utility of non-invasive measures of cardiac
autonomic, electrical, and mechanical function along with
plasma electrolytes and renal function in ambulant out-
patients with CHF. The present report describes the relation
between these variables and sudden cardiac death and the
development and utility of an index integrating these




UK-HEART was a multicentre study carried out in eight UK
institutions. We have previously published details of the
study design.10–12 In brief, ambulant outpatients of either sex
18 to 85 years old were recruited. Patients were eligible for
the study if they had stable clinical signs and symptoms of
CHF present for at least three months. Patients were in New
York Heart Association (NYHA) functional class I–III and had
objective evidence of cardiac dysfunction (pulmonary venous
congestion, pulmonary oedema or a cardiothoracic ratio
. 0.55 on at least one chest radiograph, or a documented
radionuclide or echocardiographic ejection fraction of
Abbreviations: CHF, chronic heart failure; CI, confidence interval;
MADIT II, multicentre automatic defibrillator implantation trial II; NYHA,
New York Heart Association; ROC, receiver operating characteristic;
QTc, QT interval corrected for rate; UK-HEART, United Kingdom-heart
failure evaluation and assessment of risk trial
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, 45%). A number of carefully performed population studies
have reported that up to 40% of incident and 50–60% of
prevalent CHF cases occur in the setting of preserved left
ventricular function.13 Consonant with this, a reduced
ejection fraction was not an absolute requirement for entry
into UK-HEART. Patients were excluded if they had a co-
morbid condition associated with impaired autonomic func-
tion (including diabetes mellitus). Other exclusion criteria
have been documented previously.10–12 Studies were carried
out in accordance with the standards of the local ethical
committees and with the Declaration of Helsinki. All patients
gave written informed consent to take part in the study.
Clinical data collection
At the time of recruitment, a case record form detailing
baseline clinical and demographic data was completed for all
patients. An erect posteroanterior chest radiograph was
obtained and the cardiothoracic ratio was measured. A
venous blood sample was taken at rest for assessment of
electrolyte concentration and of renal and liver function. Two
dimensional and M mode echocardiography was performed
in accordance with the American Society of Echocardio-
graphy recommendations. Left ventricular cavity dimensions
and ejection fraction were derived from the M mode
echocardiograms with standard formulas. Study patients
were registered with the UK national death reporting
scheme, which notified the steering committee of all deaths.
Twelve lead ECG analysis
Standard 12 lead ECGs were recorded at 25 mm/s and
analysed by a senior cardiologist blinded to patient char-
acteristics. The QT interval and QRS durations were
measured manually and in the case of QT, corrected for rate
(QTc) as previously described.11 To evaluate the possible role
of local dispersion of repolarisation in predicting sudden
death we calculated QTc dispersion across leads V1–V6.14 QTc
and QRS dispersions were defined as the difference between
the maximum and minimum QTc or QRS values, respectively,
occurring in any of the 12 ECG leads or leads V1–V6. Left
ventricular hypertrophy was assessed by the Sokolow-Lyon
voltage criteria.15
Ambulatory ECG
Twenty four hour ambulatory ECGs (Tracker, Reynolds
Medical, Hertford, UK) were obtained from all patients
during normal, unrestricted, out of hospital activity.
Recordings were analysed with a Reynolds Medical
Pathfinder system by independent technical staff blinded to
patient characteristics. Time and frequency domain were
analysed as previously described10 12 16 Non-sustained ventri-
cular tachycardia was defined as three or more consecutive
ventricular extrasystoles at a rate . 120 beats/min.
Classification of mode of death
Classification criteria for the cause of death were defined
before the study commenced and were based on established
definitions.17 All deaths reported to the steering committee
were evaluated by at least two senior physicians, who
reviewed death certificates, necropsy findings, and hospital
and general practitioners’ records. The mode of death was
classified as follows: (1) sudden if it occurred within one
hour of a change in symptoms or during sleep or while the
patient was unobserved and had previously been clinically
stable; (2) progressive heart failure if death occurred after a
documented period of symptomatic or haemodynamic
deterioration; (3) other cardiovascular if death did not occur
suddenly and was not associated with progression of heart
failure—this category included patients who died of acute
coronary syndromes; and (4) non-cardiovascular death.
Statistical analysis
The analytical goal was to identify independent predictors of
sudden cardiac death. Additionally, we aimed to construct a
simple predictive score that could be used in routine clinical
practice to identify patients with CHF who are at increased
risk of sudden death. Statistical analyses were completed
with SPSS (version 10; SPSS Inc, Chicago, Illinois, USA), SAS
(versions 6.12 and 8.2; SAS Institute Inc, Cary, North
Carolina, USA), and S-Plus (version 2000 Professional
Release 1, MathSoft Inc, Cambridge, Massachusetts, USA).
Descriptive group data are given as mean (SD) for continuous
variables (medians and quartiles for non-normally distrib-
uted data) and percentages for categorical data.
Cox proportional hazards regression
Stepwise Cox proportional hazards regression18 was used to
determine which measurements were significantly related to
mortality during the follow up period. To maximise the
number of observations available for the present analysis,
missing values for any variable were estimated by multiple
regression from their relation with other variables by using
the missing data facility within SPSS. Natural logarithms
were used for all heart rate variability measurements and
cardiothoracic ratio.
Variables entered into the sudden death model
In initial univariate and multivariate analyses neither time
nor frequency domain measurements of heart rate variability
were significant independent predictors of sudden death and
therefore were not considered in the present model (table 1).
Age, sex, the presence of non-sustained ventricular
tachycardia and left ventricular hypertrophy, left ventricular
end diastolic and end systolic diameters, ejection fraction,
sodium, potassium, urea, and creatinine concentrations, the
logarithm of the cardiothoracic ratio, natural logarithms of
QTc dispersion, QTc dispersion across leads V1–V6, maximum
QTc interval, and QRS dispersion were all univariate
predictors of sudden death and were therefore entered into
the statistical model. The assumption of proportional hazards
was tested and was fulfilled. Hazard ratios and 95%
confidence intervals (CI) are presented. Kaplan-Meier cumu-
lative mortality curves were produced to display the propor-
tion of patients free from sudden death over time for each of
the independent predictors.
Derivation and discrimination of predictive model
A prognostic index to predict sudden death was derived for
each patient based on the Cox proportional hazards model.19
To maximise the information supplied from the Cox model,
the parameter estimates were used to obtain an index. A
score for each of the significant independent predictors was
calculated for each patient by multiplying their value of the
factor with the parameter estimate. A sudden cardiac death
index for each patient was then derived from the sum of
these scores. We used receiver operating characteristic (ROC)
analysis to quantify the diagnostic accuracy of our index.
ROC curves plot the sensitivity against 1 – specificity by
varying the threshold value for the test. They illustrate which
threshold is a good compromise between high sensitivity and
high specificity.20 The area under the curve (C statistic) was
calculated. An area of 0.5 indicates that the test results are no
better than those obtained by chance, whereas an area of 1.0
indicates a perfectly sensitive and specific test.
RESULTS
Characteristics of UK-HEART population
Five hundred and fifty three patients were recruited. The
patients’ mean (SEM) age was 62.7 (0.41) years (range 18–85
years) and 76% were men. Two per cent were in NYHA class I,
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59% in class II, and 39% in class III. The average NYHA
functional class was 2.3 (0.02). Mean (SD) creatinine
concentration was 121 (1.8) mmol/l (range 60–340 mmol/l).
Mean (SD) sodium concentration was 140 (0.14) mmol/l
(range 122–148 mmol/l). Seventy six per cent of patients had
ischaemic heart disease as the cause of their heart failure, 199
(36%) had non-sustained ventricular tachycardia, and 54
(9.8%) had left ventricular hypertrophy. The majority of
patients (81%) were treated with angiotensin converting
enzyme inhibitors (mean (SD) dose of 12.4 (0.34) mg
(enalapril equivalent)) and loop diuretics (97% of patients,
mean (SD) furosemide (frusemide) dose 75.4 (2.9) mg).
Nineteen per cent of patients were taking digoxin (mean dose
198 (7.12) mg), 14% amiodarone (all patients 200 mg), and
7.9% atenolol (mean dose 43.7 (1.6) mg). Data on five year
survival status was available for all patients. At five years
(2365 patient-years), 201 patients had died (mean annual
mortality rate 7.3%) with 67 sudden deaths.
Predictors of sudden cardiac death
Cox multivariate independent predictors of sudden death
shown in table 2 were cardiothoracic ratio, QRS dispersion,
QTc dispersion across leads V1–V6, and the presence of non-
sustained ventricular tachycardia. Kaplan-Meier curves (fig 1)
show the proportion of patients free from sudden death with
variables dichotomised by median values or in the case of
non-sustained ventricular tachycardia its presence or
absence.
In a preliminary report10 (follow up 482 (161) days) with
only 18 sudden deaths serum potassium was a weak
predictor of sudden death. In the present analysis, which
has far greater statistical power and incorporated QTc and
QRS measurements in the sudden death model, potassium is
not an independent predictor of sudden death.
QRS dispersion or maximum QRS as a predictor of
sudden death
The recently published MADIT II (multicentre automatic
defibrillator implantation trial II)7 suggested that patients
with previous myocardial infarction and an ejection fraction
, 30% with a QRS duration . 120 ms benefited most from
implantable cardioverter-defibrillators. To explore the possi-
bility that the prognostic value of QRS dispersion was simply
a reflection of maximum QRS duration, we analysed the
same model but with QRS dispersion being replaced by QRS
minimum and QRS maximum durations. While QRS max-
imum alone also gave predictive information it did not reach
the same level of significance as QRS dispersion.
Characteristics of survivors and of patients who died
suddenly and non-suddenly
Comparing the characteristics of survivors, patients who died
suddenly, and those who died non-suddenly showed a
significant difference between the three groups. However,
the value of any measurement to predict sudden death is in
its ability to identify patients at increased risk of sudden
death and to discriminate between patients who die suddenly
and those who die non-suddenly. In the present cohort the
phenotypes of these patients were very similar in demo-
graphic, echocardiographic, and ECG data. No single mea-
surement alone separated the two groups (table 3). Hence we
integrated the four independent predictors of sudden death
to develop a predictive model.
Development of predictive model of sudden death
To explore the utility of combining the four independent
predictors to identify patients at increased risk of sudden
death, we derived a prognostic index based on the
importance of each predictor in the Cox model. The natural
logarithm of the patient’s cardiothoracic ratio, QRS disper-
sion, and QTc dispersion was calculated. These figures were
then multiplied by 3.75, 1.10, and 0.36, respectively, and the
sum was calculated. An additional score of 0.71 was added if
non-sustained ventricular tachycardia was present (no score
was added if it was not present). The resulting score ranged
from approximately 1.28 to 3.80 with a higher score denoting
increased risk of sudden cardiac death within five years.
When dividing the UK-HEART population into deciles, for
patients with the highest score (56 patients) the index had a
positive predictive value of 37.5, negative predictive value of
90.7, sensitivity of 31.3, and specificity of 92.8. We used the
bootstrap method (S-Plus) to validate the model and found
that with 20 000 bootstrap samples, 95% of sensitivity values
fell between 53.5% and 76.6% indicating that the index has
good potential to be useful in other similar populations of
CHF patients.
Table 1 Univariate logistic regression for time and frequency domain heart rate
variability measurements and sudden death status at five years
Measurement
Odds ratio for sudden death for every
10% decrease in variable (95% CI) p Value
SDNN (ms) 0.95 (0.88 to 1.02) 0.15
Very low frequency power (ms2) 1.01 (0.95 to 1.08) 0.63
Low frequency power (ms2) 0.96 (0.78 to 1.19) 0.74
High frequency power (ms2) 0.98 (0.84 to 1.14) 0.84
Total power (ms2) 1.00 (0.95 to 1.05) 0.80
CI, confidence interval; SDNN, standard deviation of all NN intervals.







(95% CI) p Value
Cardiothoracic ratio (10% increase) 3.75 (0.96) 15.3 1.43 (1.20 to 1.71) 0.001
NSVT (present) 0.71 (0.24) 8.7 2.03 (1.27 to 3.25) 0.003
QRS dispersion (10% increase) 1.10 (0.36) 9.2 1.11 (1.04 to 1.19) 0.002
QTc dispersion V1–V6 (10% increase) 0.36 (0.17) 4.4 1.03 (1.00 to 1.07) 0.035
P values are based on Cox proportional hazards model.
NSVT, non-sustained ventricular tachycardia; QTc, QT interval corrected for rate.
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Accuracy of the predictive model in CHF subgroups
To further explore the diagnostic accuracy of this index we
constructed ROC curves (not shown). The C statistic for this
index to predict sudden death within the whole UK-HEART
population was 0.71 (95% CI 0.64 to 0.78). We further
analysed patients with ischaemic heart disease and ejection
fractions less than 45%. Applied to this patient group
(n = 262) the index improved in its predictive value and
discrimination (C statistic 0.76, 95% CI 0.68 to 0.84). When
the group of patients with ejection fractions , 45% and
ischaemic heart disease was divided into deciles, for patients
with the highest score (39 patients) the index had a positive
predictive value of 38.5, negative predictive value of 89.7,
sensitivity of 39.5, and specificity of 89.3. We used the
bootstrap method to validate this model and found that with
20 000 bootstrap samples, 95% of sensitivity values fell
between 54.7% and 84.2% indicating that the index has good
potential to be useful in another similar population of CHF
patients.
DISCUSSION
It is well established that patients with mild to moderate CHF
are at relatively greater risk of sudden death than patients
with more substantial functional impairment.5 Unfortunately
there has been no reliable and simple method of identifying
‘‘high risk’’ patients within this group. The present report
describes a number of novel and potentially important
findings. Firstly, a chest radiograph, 12 lead ECG, and 24
hour ECG can provide information allowing the identification
of patients at substantially increased risk of sudden death.
Secondly, measurement of QT dispersion across leads V1–V6
provides useful prognostic information, whereas QT disper-
sion across the 12 lead ECG does not. Thirdly, in the present
population of patients with mild to moderate CHF measure-
ments of heart rate variability did not provide information
identifying patients at risk of sudden death. In a previous
report we showed that heart rate variability can predict
progressive heart failure death.12 The potential mechanisms
are discussed in detail in that report. Fourthly, QRS
dispersion provides additional prognostic information to
QRS maximum. Lastly, we have shown that the integration
of four non-invasive measurements has the potential to
identify patients at high risk of dying suddenly as opposed to
dying non-suddenly over a five year period.
Study population
We studied patients with both ischaemic and non-ischaemic
causes of CHF and we included patients with preserved
systolic function. Our index performed well in identifying
members of this heterogeneous group at risk of sudden
death. Studies have suggested that the mechanisms of
ventricular arrhythmia in ischaemic heart disease and non-
ischaemic cardiomyopathy may be different. Furthermore,
more sophisticated investigation and treatments apply only
to patients with ischaemic heart disease and impaired systolic
function. When applied to this group our index performed
even better, supporting its potential as an initial risk
stratification tool for identifying patients with mild to
Figure 1 Kaplan-Meier curves showing proportions of patients free from sudden death over five years when patients are dichotomised by median
value of (A) QRS dispersion, (B) QT dispersion across leads V1–V6 corrected for rate (QTc), (C) the presence or absence of non-sustained ventricular
tachycardia (NSVT), and (D) cardiothoracic ratio dichotomised by median.
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moderate ischaemic heart failure at increased risk of sudden
death, who may benefit from more intensive evaluation and
treatment.
Electrical inhomogeneity and its relation to sudden
death
It is likely that the major electrical feature necessary for the
development of sustained ventricular tachyarrhythmias and
thus sudden death is electrical inhomogeneity.21 In the
normal heart there is some degree of electrical inhomogeneity
due to the different cell types present. This inhomogeneity
becomes more pronounced in the failing heart producing
conditions that are favourable for the induction of sustained
re-entrant ventricular tachycardia. As the QRS complex is
thought to represent ventricular depolarisation, increased
QRS dispersion on the 12 lead ECG may represent inhomo-
geneity of depolarisation, creating an environment that
substantially increases the likelihood of initiating a re-entry
circuit. A link between inhomogeneous electrical depolarisa-
tion and arrhythmic death in tetralogy of Fallot,22 arrhythmic
right ventricular cardiomyopathy,23 and severe CHF24 has
been postulated. The present study is the first to address this
question in a large prospective study of patients with mild to
moderate CHF.
The QT interval is thought to represent electrical repolar-
isation and it has been proposed that increased QT dispersion
is indicative of inhomogeneous repolarisation. No study has
shown unequivocally that measurements of QT dispersion
obtained from a standard 12 lead ECG are related to
increased risk of sudden death in CHF.11 25 The present study
confirms this but has produced the novel finding that the
measurement of QT dispersion across leads V1–V6 is a
potential prognostic tool to predict future arrhythmic events.
This finding may be due to these measurements being more
closely related to inhomogeneity of repolarisation across a
scarred left ventricle when compared with QT dispersion
measured from all 12 ECG leads.14 It is a finding that
warrants further study.
Cardiothoracic ratio and sudden death
We showed that the greater a patient’s cardiothoracic ratio,
the greater their risk of sudden death. In our dataset, there
was only a weak correlation between cardiothoracic ratio and
left ventricular cavity internal dimensions. The cardiothoracic
ratio may therefore provide information about overall cardiac
morphology and interaction with the lungs. Myocardial
stretch due to mechanical loading can increase refractoriness,
trigger afterdepolarisations and ventricular extrasystoles, and
slow conduction favouring re-entry and arrhythmia.
Consistent with this hypothesis, a recent study from Berger
and colleagues26 showed that increased plasma B type
natriuretic peptide concentrations (a marker of ventricular
stretch) are an independent predictor of sudden death in
patients with severe CHF (as shown by ejection fractions less
than 20%). These findings suggest that mechanoelectrical
interaction may have an important role in the pathogenesis
of sudden death in CHF. The positive predictive value of
plasma B type natriuretic peptide concentrations to predict
sudden death in this study, however, was less than 20%. The
integrated index derived from UK-HEART had a positive
predictive value of about 40%, a value that to our knowledge
is the best of any current method of predicting sudden death
in patients with CHF.4
Relevant to our finding of a relation between cardiothor-
acic ratio and sudden death is the finding that the occurrence
of ventricular arrhythmia and sudden death has been shown
to be closely related to lung function.27 28 Substantial
cardiomegaly in patients with CHF may interfere with
Table 3 Characteristics of patients according to outcome
Study population Survivors Sudden death Non-sudden death p Value
UK-HEART (n = 553) n = 352 n =67 n =134
Age (years) 61.8 (9.6) 62.4 (9.9) 64.2 (9.2) 0.002
Male sex 74.4% 73.1% 82.8% 0.121
NYHA class III 29.8% 49.3% 57.5% ,0.001
LVEF (%) 44.0 (17) 36.2 (14) 38.5 (15) ,0.001
LVESD (cm) 4.88 (1.1) 5.50 (1.0) 5.31 (1.2) ,0.001
LVEDD (cm) 6.08 (0.9) 6.53 (0.9) 6.41 (1.1) ,0.001
CTR (%) 0.51 (0.48–0.55) 0.57 (0.52–0.60) 0.55 (0.50–0.60) ,0.001
NSVT present 31.2% 56.7% 48.5% ,0.001
LVH present 8.0% 10.4% 16.4% 0.023
Heart rate (beats/min) 72.5 (64–84) 76.8 (64–89) 77.0 (68–89) 0.037
QRS dispersion (ms) 41.3 (34–49) 47.0 (39–59) 43.3 (37–54) 0.003
QTc dispersion leads V1–V6 (ms) 35.0 (24–49) 42.0 (31–63) 37.0 (28–50) 0.009
Sudden cardiac death score 3.07 (0.73) 3.86 (0.84) 3.55 (0.74)** ,0.001
IHD and LVEF ,45% (n = 262) n = 148 n =38 n =76
Age (years) 61.7 (8.2) 63.7 (8.5) 64.0 (8.8) 0.106
Male sex 81.1% 73.7% 89.5% 0.091
NYHA class III 40.5% 60.5% 56.6% 0.019
LVEF (%) 30.9 (8.5) 28.2 (10.1) 29.9 (8.5) 0.224
LVESD (cm) 5.46 (0.9) 5.78 (1.0) 5.78 (1.0) 0.027
LVEDD (cm) 6.35 (0.8) 6.58 (0.9) 6.69 (1.0) 0.025
CTR (%) 0.52 (0.48–0.54) 0.57 (0.55–0.60) 0.55 (0.50–0.61) ,0.001
NSVT present 34.5% 65.8% 50.0% 0.001
LVH present 4.7% 13.2% 13.2% 0.051
Heart rate (beats/min) 74.6 (66–83) 76.9 (60–89) 75.2 (66–89) 0.573
QRS dispersion (ms) 42.3 (35–51) 47.3 (39–59) 44.0 (35–54) 0.061
QTc dispersion leads V1–V6 (ms) 34.9 (24–48) 43.5 (32–74) 37.0 (30–54) 0.011
Sudden cardiac death score 3.17 (0.71) 4.09 (0.73) 3.61 (0.79)* ,0.001
The only significant difference between patients who died suddenly and patients who died non-suddenly were for the sudden cardiac death index (*p = 0.002;
**p = 0.009).
Values are mean (SD) (analysis of variance), medians (quartiles) (Kruskal-Wallis test), or percentages (x2 test).
CTR, cardiothoracic ratio; IHD, ischaemic heart disease; LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end systolic diameter; LVH, left ventricular hypertrophy; NYHA, New York Heart Association; UK-HEART, United Kingdom-heart failure evaluation and
assessment of risk trial.
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normal lung function, providing a further mechanism to
explain the observed relation between cardiomegaly and
sudden cardiac death.
Effect of non-sustained ventricular tachycardia on risk
of sudden cardiac death
The majority of studies exploring the relation between non-
sustained ventricular tachyarrhythmias and sudden cardiac
death have been retrospective analyses of patients with
severe heart failure taking part in trials of therapeutic
agents.29 30 In a long term prospective study designed
specifically to evaluate prognostic markers, we have con-
firmed that the presence of non-sustained ventricular
tachyarrhythmia in patients with mild to moderate CHF is
an ominous sign, increasing the risk of sudden death
twofold. The relation between non-sustained ventricular
tachycardia and sustained ventricular tachycardia is far from
clear.21 Despite this, in our cohort non-sustained ventricular
tachycardia in association with evidence of cardiac dilatation
and inhomogeneity of depolarisation/repolarisation was a
combination that clearly identified patients at increased risk
of sudden (presumably) arrhythmic death.
Performance of sudden cardiac death index
The present analysis aimed at constructing an index that
could identify patients specifically at increased risk of sudden
death. The mechanisms underlying this are complex and
multifactorial. In keeping with this the index required four
independent predictors from a rigorous multivariate analysis.
The C statistics of 0.71 for the whole population and 0.76 for
patients with systolic dysfunction secondary to ischaemic
heart disease illustrate the ability of our index to discriminate
between patients at increased risk of sudden death per se.
An important role of an index predicting sudden death is
its ability to discriminate between patients who die suddenly
and those who die non-suddenly. When comparing the scores
of these groups in our whole population and in patients with
ischaemic heart disease underlying their CHF, our index
allowed us to distinguish one group from the other. As with
all prognostic indices the present data should be tested in
different heart failure populations in different geographical
locations to assess whether its discrimination degrades in
separate cohorts.31 If the value of this index holds up in other
studies, it offers a means of cost effectively targeting
expensive interventions into a high risk subgroup of patients
with CHF. Preventing sudden death is very important for
patients with mild to moderate CHF, since their pump
function is adequate to maintain a good quality of life for
long term survivors.
Study limitations
As in all studies of this nature, classification of death is a
potential problem, in particular attribution of sudden death
to cardiac arrhythmia. We used strict predefined criteria for
classification of death, which was carried out by senior
physicians blinded to patient details. It has been suggested
that sudden death in heart failure is not just due to
arrhythmia and may be due to bradycardia or electromecha-
nical dissociation in some patients.32 It is likely, however, that
these are a feature of more severe heart failure, whereas our
cohort had mild to moderate CHF based on both sympto-
matic and echocardiographic data. Another potential limita-
tion of the present study is that while the majority of patients
were stabilised with angiotensin converting enzyme inhibi-
tors, the study commenced and follow up finished just as the
landmark trials of b blockers in mild to moderate CHF were
being published. It would hence not be possible to have five
year follow up of patients all taking these agents at present.
However, in these studies patients with an ejection fraction
. 40% were excluded. The UK-HEART study was designed
such that our population represented more accurately the
usual CHF population with about 40% having preserved
ejection fractions. There is thus no evidence as yet to support
b blocker use in a substantial proportion of the UK-HEART
and wider CHF population. Despite this our findings should
be tested in a population taking b blockers. The present study
excluded diabetic patients and, therefore, we cannot extra-
polate from our data to the diabetic population.
Conclusion
The present study shows that it is possible to identify patients
with mild to moderate CHF at increased risk of sudden death
from 12 lead and 24 hour ECGs and a posteroanterior chest
radiograph. Whether these new findings can be used in
tailoring treatment or targeting investigations warrants
further studies.
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Echolucent neointimal hyperplasia ‘‘dark wall’’ after sirolimus eluting stent implantation
A
45 year old man was admitted because
of exertional angina. Coronary angio-
graphy revealed a 70% stenosis in the
left circumflex artery (LCx). He was enrolled
in the US SIRIUS study to evaluate the
efficacy of sirolimus eluting stents in de novo
native coronary lesions. A dramatic reduc-
tion of restenosis has previously been
demonstrated using sirolimus eluting stents.
A 3.06 18 mm sirolimus eluting stent
(Cordis, Johnson & Johnson, Miami,
Florida, USA) was deployed in the distal
LCx lesion. Eight months later, angiography
and intravascular ultrasound (IVUS) were
performed according to the study protocol
(see fig), although he had been asympto-
matic. IVUS imaging demonstrated non-
obstructive, eccentric echolucent tissue in
the proximal part of the stent, which
corresponded to the angiographic mild,
eccentric luminal narrowing. No further
procedure was performed.
Echolucent tissue, which is termed ‘‘black
hole’’ and more appropriately ‘‘black wall’’,
has been reported after intracoronary brachy-
therapy. The tissue specimens obtained
by atherectomy in a limited number of
cases demonstrated that the echolucent
findings appeared to be caused by a
hypocellular matrix with areas of proteo-
glycan. Proteoglycan has a high water
content that may explain the IVUS fea-
tures. While we do not have histological
data on this patient, the echolucent tissue
in this patient may likewise be caused by






White arrows in angiogram (top) correspond to the segment of the circumflex coronary artery
depicted in the intravascular ultrasound (IVUS) imaging sequence (bottom). Arrowheads in
angiogram indicate the edges of the stent. IVUS images are displayed from distal (on left) to
proximal (on right). Individual images are 1 mm apart to illustrate a 7 mm length of the proximal
part of the stent. Each image except the most right and left demonstrates crescent shaped, echolucent
neointima (white arrowheads) inside the stent.
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